Septerna, Inc.
NASDAQ:SEPNBiotechnology
-$0.73 today
- Market cap
- $1.88B
- Beta
- 2.38
- P/E (TTM)
- -43.6
- EPS (TTM)
- -$0.81
Volume 0.30M
Average 0.32M
SEPN Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Septerna, Inc.NASDAQ: SEPN
Net Margin · Q3 FY2026 · quarter ended Sep 2026
Net margin narrows to -140.8%
Net margin was -140.8% in Q3 FY2026, down 178.9 pp from a year earlier. On a trailing-twelve-month basis it was -61.3%, up 205.5 pp year over year.
Context
- Net margin widened in 1 of the last 2 fiscal years.
What to watch
Whether net margin reaches the consensus estimate from 7 analysts of -49.2% for the fiscal year ending Dec 2026, up from -106.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -140.8%-92.1 pp QoQ
- Last fiscal yearDec 2025
- -106.4%+6572.5 pp YoY
- LTMSep 2026
- -61.3%+205.5 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -178.9 pp | -64.6 pp | +114.3 pp |
| 1 year | +6572.5 pp | +57.2 pp | -6515.3 pp |
| 3 years | — | -61.5 pp | — |
| 5 years | -69.0 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -106.4%
- Year-over-year change
- +6572.5pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -106.4% | +6572.5pp |
| FY2024 | 2024-12-31 | -6678.9% | -9447.1pp |
| FY2023 | 2023-12-31 | 2768.2% | — |
Net Margin vs competitors
How SEPN compares with its peers on the latest reported figures
- SEPN's LTM Sep 2026 net margin of -61.3% is the 2nd highest of the 3 companies compared; the peer median is -303.3%.
- Its year-over-year change of +205.5 pp is the 2nd highest of 3, against a peer median of +54648.8 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 6.1% | +109941.4 pp | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | -61.3% | +205.5 pp | — |
| LTM Mar 2026 | -612.7% | -643.7 pp | — | |
MBXMBX Biosciences, Inc. Common Stock | FY2025 | — | — | — |
KLRAKailera Therapeutics, Inc. | FY2025 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding SEPN) | -303.3% | +54648.8 pp | — | |
Competitors are the stored peer set for SEPN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|
| Revenue | 151K | 1.08M | 45.95M |
| Cost of Revenue | 0 | 0 | 0 |
| Gross Profit | 151K | 1.08M | 45.95M |
| Gross Margin | 100.0% | 100.0% | 100.0% |
| Research & Development | 35.98M | 65.34M | 97.58M |
| Selling, General & Admin | 9.72M | 16.56M | 29.16M |
| Operating Expenses | (1.92M) | 81.9M | 126.75M |
| Depreciation & Amortization | 848K | 1.4M | 1.6M |
| EBITDA | (44.7M) | (70.9M) | (47.26M) |
| EBITDA Margin | -29604.0% | -6594.9% | -102.9% |
| Operating Income | 2.08M | (80.82M) | (80.8M) |
| Operating Margin | 1374.2% | -7518.4% | -175.8% |
| Interest Income | 2.79M | 8.62M | 19.53M |
| Interest Expense | 0 | 0 | 0 |
| Other Income / Expenses | 2.8M | 8.53M | 31.93M |
| Income Before Tax | 4.87M | (72.3M) | (48.87M) |
| Pre-Tax Margin | 3225.8% | -6725.2% | -106.3% |
| Income Tax Expense | 691K | (498K) | 12K |
| Net Income | 4.18M | (71.8M) | (48.88M) |
| Net Margin | 2768.2% | -6678.9% | -106.4% |
| EPS (Basic) | 0.03 | (1.93) | (1.10) |
| EPS (Diluted) | 0.03 | (1.93) | (1.10) |
| Weighted Avg Shares | 19.5M | 37.19M | 44.26M |
| Weighted Avg Shares (Diluted) | 19.5M | 37.19M | 44.26M |
Septerna, Inc.
NASDAQ:SEPN
Intrinsic Alpha fair value
Locked
Current Price
$39.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.